Clinical Trial Update: Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 study of GS-9450 for chronic hepatitis C virus infection has been terminated; the update notes status but does not provide efficacy or safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-9450

Snippet

Sponsor: Gilead Sciences | Conditions: HCV Infection | Phase 2 | Status: TERMINATED